Literature DB >> 20350793

Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.

Jean L Wright1, Sujata M Patil, Larissa K F Temple, Bruce D Minsky, Leonard B Saltz, Karyn A Goodman.   

Abstract

PURPOSE: Intensity-modulated radiation treatment (IMRT) is increasingly used in the treatment of squamous cell carcinoma of the anal canal (SCCAC). Prevention of locoregional failure (LRF) using IMRT requires appropriate clinical target volume (CTV) definition. To better define the CTV for IMRT, we evaluated patterns and predictors of LRF in SCCAC patients given conventional radiation treatment. METHODS AND MATERIALS: We reviewed records of 180 SCCAC patients treated with conventional radiation with or without chemotherapy at our institution between January 1990 and March 2007. All patients received radiation; the median primary tumor dose was 45 Gy. A total of 173 patients also received mitomycin-based chemotherapy.
RESULTS: Median follow-up was 40 months. Actuarial 3-year colostomy-free survival was 89% and overall survival (OS) 88%. Actuarial 3-year LRF was 23%. A total of 45 patients had LRF, with 35 (78%) occurring locally in the primary site (25 local only, 10 local and regional); however, 20 (44%) had regional components of failure within the pelvis or inguinal nodes (10 regional only, 10 local and regional). Cumulative sites of LRF (patients may have one or more site of failure) were as follows: primary, 35; inguinal, 8; external perianal, 5; common iliac, 4; presacral, 3; distal rectum, 2; external iliac, 2; and internal iliac, 2. All patients with common iliac failure had cT3 or N+ disease.
CONCLUSIONS: The observed patterns of failure support inclusion of the inguinal and all pelvic nodal groups in the CTV for IMRT. In patients with advanced tumor or nodal stage, common iliac nodes should also be included in the CTV.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350793     DOI: 10.1016/j.ijrobp.2009.09.029

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

Review 1.  New approach to anal cancer: individualized therapy based on sentinel lymph node biopsy.

Authors:  Paola De Nardi; Michele Carvello; Carlo Staudacher
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

2.  Does endoscopic ultrasound improve detection of locally recurrent anal squamous-cell cancer?

Authors:  Carrie Y Peterson; Martin R Weiser; Philip B Paty; Jose G Guillem; Garrett M Nash; Julio Garcia-Aguilar; Sujata Patil; Larissa K Temple
Journal:  Dis Colon Rectum       Date:  2015-02       Impact factor: 4.585

3.  Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT.

Authors:  V Dell'Acqua; J Kobiela; F Kraja; M C Leonardi; A Surgo; M A Zerella; S Arculeo; C Fodor; R Ricotti; M G Zampino; S Ravenda; G Spinoglio; R Biffi; A Bazani; R Luraschi; S Vigorito; P Spychalski; R Orecchia; R Glynne-Jones; B A Jereczek-Fossa
Journal:  Med Oncol       Date:  2018-03-28       Impact factor: 3.064

4.  Patterns of failure for stage I ampulla of Vater adenocarcinoma: a single institutional experience.

Authors:  Jim Zhong; Manisha Palta; Christopher G Willett; Shannon J McCall; Frances McSherry; Douglas S Tyler; Hope E Uronis; Brian G Czito
Journal:  J Gastrointest Oncol       Date:  2014-12

Review 5.  Technical aspects of radiation therapy for anal cancer.

Authors:  Eli D Scher; Inaya Ahmed; Ning J Yue; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2014-06

6.  Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.

Authors:  Lisa A Kachnic; Kathryn A Winter; Robert J Myerson; Michael D Goodyear; Andre A Abitbol; Oscar E Streeter; Mark E Augspurger; Tracey E Schefter; Alan W Katz; Barbara J Fisher; Lauren E Henke; Samir Narayan; Christopher H Crane
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-14       Impact factor: 8.013

Review 7.  Anal cancer: are we making progress?

Authors:  Ajay Aggarwal; Simon Duke; Rob Glynne-Jones
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

8.  Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?

Authors:  Christoph Henkenberens; Daniela Meinecke; Stoll Michael; Michael Bremer; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2015-08-26       Impact factor: 3.621

Review 9.  Squamous-cell carcinoma of the anus: progress in radiotherapy treatment.

Authors:  Rob Glynne-Jones; David Tan; Robert Hughes; Peter Hoskin
Journal:  Nat Rev Clin Oncol       Date:  2016-01-27       Impact factor: 66.675

10.  Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer.

Authors:  Julia Koeck; Frank Lohr; Daniel Buergy; Karen Büsing; Marcus J Trunk; Frederik Wenz; Sabine Mai
Journal:  Radiat Oncol       Date:  2016-04-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.